Group One Trading’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.34M | Buy |
32,100
+13,700
| +74% | +$3.07M | 0.01% | 1034 |
|
|
2025
Q4 | $3.92M | Sell |
18,400
-3,200
| -15% | -$661K | 0.01% | 1714 |
|
|
2025
Q3 | $4.29M | Buy |
21,600
+20,200
| +1,443% | +$3.77M | 0.01% | 1612 |
|
|
2025
Q2 | $242K | Buy |
1,400
+1,200
| +600% | +$195K | ﹤0.01% | 4148 |
|
|
2025
Q1 | $31.2K | Sell |
200
-5,100
| -96% | -$729K | ﹤0.01% | 5520 |
|
|
2024
Q4 | $730K | Sell |
5,300
-6,100
| -54% | -$802K | ﹤0.01% | 2860 |
|
|
2024
Q3 | $1.7M | Buy |
11,400
+10,100
| +777% | +$1.36M | ﹤0.01% | 1845 |
|
|
2024
Q2 | $177K | Sell |
1,300
-100
| -7% | -$13.6K | ﹤0.01% | 3501 |
|
|
2024
Q1 | $212K | Buy |
1,400
+1,000
| +250% | +$143K | ﹤0.01% | 3517 |
|
|
2023
Q4 | $50.4K | Sell |
400
-400
| -50% | -$39.9K | ﹤0.01% | 5053 |
|
|
2023
Q3 | $74.9K | Sell |
800
-15,100
| -95% | -$1.41M | ﹤0.01% | 4721 |
|
|
2023
Q2 | $1.42M | Sell |
15,900
-38,900
| -71% | -$3.39M | ﹤0.01% | 2020 |
|
|
2023
Q1 | $5.88M | Buy |
54,800
+30,300
| +124% | +$3.47M | 0.02% | 759 |
|
|
2022
Q4 | $2.99M | Sell |
24,500
-17,700
| -42% | -$2.06M | 0.01% | 1491 |
|
|
2022
Q3 | $4.36M | Buy |
+42,200
| New | +$4M | 0.01% | 1271 |
|
|
2022
Q2 | – | Sell |
-1,900
| Closed | -$223K | – | 7764 |
|
|
2022
Q1 | $223K | Buy |
+1,900
| New | +$220K | ﹤0.01% | 4687 |
|
|
2021
Q4 | – | Sell |
-500
| Closed | -$80K | – | 8163 |
|
|
2021
Q3 | $80K | Buy |
500
+300
| +150% | +$41.1K | ﹤0.01% | 6123 |
|
|
2021
Q2 | $26K | Sell |
200
-200
| -50% | -$26.6K | ﹤0.01% | 7031 |
|
|
2021
Q1 | $52K | Buy |
+400
| New | +$60.8K | ﹤0.01% | 6189 |
|
|
2020
Q4 | – | Sell |
-5,100
| Closed | -$787K | – | 6462 |
|
|
2020
Q3 | $787K | Sell |
5,100
-2,100
| -29% | -$302K | ﹤0.01% | 2416 |
|
|
2020
Q2 | $1.06M | Buy |
7,200
+7,000
| +3,500% | +$961K | ﹤0.01% | 1963 |
|
|
2020
Q1 | $23K | Sell |
200
-900
| -82% | -$117K | ﹤0.01% | 4152 |
|
|
2019
Q4 | $153K | Buy |
1,100
+100
| +10% | +$11.1K | ﹤0.01% | 3350 |
|
|
2019
Q3 | $96K | Sell |
1,000
-10,200
| -91% | -$1.14M | ﹤0.01% | 3585 |
|
|
2019
Q2 | $1.29M | Sell |
11,200
-53,000
| -83% | -$6.34M | 0.01% | 1419 |
|
|
2019
Q1 | $7.56M | Buy |
64,200
+64,000
| +32,000% | +$5.6M | 0.08% | 268 |
|
|
2018
Q4 | $13K | Sell |
200
-1,700
| -89% | -$107K | ﹤0.01% | 4174 |
|
|
2018
Q3 | $135K | Buy |
+1,900
| New | +$131K | ﹤0.01% | 3311 |
|
Other funds holding ASND
RCM
ACA
Group One Trading's ASND Position: Q3 2025 in Review
Group One Trading sold out of Ascendis Pharma A/S (ASND) in Q3 2025, closing a stake of 142 shares — an estimated $26.5K sold.
Group One Trading first reported a position in ASND in Q2 2018 and held it in 17 quarters. The position peaked at $1.79M in Q3 2022. 279 funds tracked by Wall St. Rank hold ASND as of Q3 2025.
- Group One Trading reported no remaining Ascendis Pharma A/S position as of Q3 2025 after selling out during the quarter.
- Group One Trading sold 142 Ascendis Pharma A/S shares in Q3 2025, an estimated $26.5K.
- Group One Trading first reported a position in Ascendis Pharma A/S in Q2 2018 and held it in 17 quarters.
- Group One Trading's Ascendis Pharma A/S position peaked at $1.79M in Q3 2022.
- 279 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2025.
Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.